OS THERAPIES INCORPORATED (OSTX) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $45.28K; Additional Paid in Capital, Common StockUSD $74.26M; Additional Paid in CapitalUSD (m).
- 2026-03-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $39.28K; Additional Paid in Capital, Common StockUSD $66.72M; Additional Paid in CapitalUSD (m).
- 2025-12-31: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $37.11K; Additional Paid in Capital, Common StockUSD $61.05M; Additional Paid in CapitalUSD (m).
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $33.27K; Additional Paid in Capital, Common StockUSD $57.33M; Additional Paid in CapitalUSD (m).
OS THERAPIES INCORPORATED Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $45.28K | $74.26M | (m) | $-86.22M | $-11.91M | (m) | 3 month · $1.33M | (m) | (m) | (m) |
| 2026-03-31 | (m) | $39.28K | $66.72M | (m) | $-77.58M | $-10.82M | (m) | 3 month · $1.44M | (m) | (m) | (m) |
| 2025-12-31 | (m) | $37.11K | $61.05M | (m) | $-67.19M | $-6.10M | (m) | 12 month · $4.27M | (m) | (m) | (m) |
| 2025-09-30 | (m) | $33.27K | $57.33M | (m) | $-53.73M | $3.64M | (m) | 3 month · $814.93K | (m) | (m) | (m) |
| 2025-06-30 | (m) | $29.66K | $51.76M | (m) | $-46.85M | $4.94M | (m) | 3 month · $905.18K | 3 month · $2.90M | 3 month · $878.15K | (m) |
| 2025-03-31 | (m) | $21.35K | $38.10M | (m) | $-42.31M | $-4.19M | $-4.19M | 3 month · $941.28K | (m) | 3 month · $330.78K | (m) |
| 2024-12-31 | (m) | $20.87K | $35.14M | $35.14M | $-38.43M | $-3.27M | $-3.27M | 12 month · $268.30K | (m) | (m) | (m) |
| 2024-09-30 | (m) | $21.18K | (m) | $34.71M | $-35.44M | $-707.13K | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $5.99K | (m) | $5.50M | $-32.57M | $-27.06M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $11.98K | (m) | $5.49M | $-31.01M | $-25.51M | $-25.51M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $1.30K | $5.34K | (m) | $5.50M | $-29.52M | $-24.02M | $-24.02M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | $-22.52M | (m) | (m) | (m) | (m) | 3 month · $757.60K |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | $-21.27M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | $-18.74M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | (m) | (m) | $-17.56M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |